证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 | --- | --- | --- | |---------------------|-------------------------|----------------------------------------------------| | | | | | | ■ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | | 西南证券何治力；华安基金袁银泉；富国基金姜恩铸；浙 | | 人员名称 | | 商证券张海涛；中信建投贺菊颖、刘若飞 | | 时间 | 2018 年 2 月 27 | 日 13:30—15:00 | | 地点 | 公司三楼会议室 | | | 上市公司接待 | | 总经理孙裕；董事会秘书吕芝瑛；证券部部长顾建军；证 | | 人员姓名 | 券事务代表安文婷 | | | 投资者关系活动 | | 总经理孙裕结合公司近期披露的 ...

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20200212 | --- | --- | --- | |-----------------------|-------------------------|------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系 | □ 新闻发布会 | □ 路演活动 | | 活动类别 | □ 现场参观 | | | | ■ 其他 | | | | | 中信建投证券"连线上市公司"活动 | | 参与单位名称 | | 中信建投证券财富管理部相关人员以及邀请 60 多名机构投资 | | 及人员名称 | 者和个人投资者 | | | 时间 | 2020 年 2 月 12 | 日下午 14:00—15:30 | | 地点 | 兰州新区华山路 | 2289 号佛慈制药科技工业园五楼会议室 | | | | 董事长石爱国先生；董事、总经理尚寿鹏先生；副总经理、 | | 上市 ...

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20180622 | --- | --- | --- | |---------------------|--------------------|------------------------------------------------------| | | | | | | □ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | | | | ■ 其他 | | | | 2018 年 6 月 | 22 日，公司举行了兰州新区佛慈制药科技工 | | 投资者关系活动 类别 | | 业园项目（以下简称"兰州新区项目"）投产启动仪式，并 | | | | 举办了"甘肃资本市场产融结合发展论坛"。公司特邀业内 | | | | 资深专家、行业分析师，机构与个人投资者，甘肃辖区部分 | | | 上市公司人员等 | 90 多人参加了上午的投产仪式，参观了兰州 | | | | 新区佛慈制药科技工业园区，并参加了下午的论坛交流活 | | | 动。 | | ...

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20181023 | --- | --- | --- | |-------------------------|--------------------------|----------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | | □ 新闻发布会 | □路演活动 | | 投资者关系活动 | □ 现场参观 | | | 类别 | ■ 其他 | | | | | 深交所联合中证中小投资者服务中心、甘肃证监局、甘肃省 | | | | 上市公司协会共同举办的"投资者服务丝路行（甘肃站） | | | ——践行中国梦 · | 走进上市公司"投资者开放日 | | | 1 资者； | 、通过广发证券、海通证券、华龙证券等报名的 50 多名投 | | 参与单位名称及 人员名称 | 省上市公司协会相关领导 ...

兰州佛慈制药股份有限公司 2022 年第三季度报告 证券代码：002644 证券简称：佛慈制药 公告编号：2022-033 兰州佛慈制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 兰州佛慈制药股份有限公司 2022 年第三季度报告 重要内容提示： （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 一、主要财务数据 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 236,625,666.66 | -14.68% | ...

兰州佛慈制药股份有限公司 2022 年半年度报告全文 兰州佛慈制药股份有限公司 2022 年半年度报告 2022 年 8 月 1 兰州佛慈制药股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 备查文件目录 一、 载有法定代表人、主管会计工作负责人、 会计机构负责人签名并盖章的财务报 告文本； 公司负责人石爱国、主管会计工作负责人冯晓云及会计机构负责人(会计 主管人员)姚毅磊声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 二、报告期内在中国证监会指定信息披露媒体上披露过的所有公司文件的正本及公告 的原稿； 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 敬请投资者 注意投资风险。 公司在本报告"第三节 管理层讨论与分析" 中分析了公司未来发展可能面 临的风险因素和应对措施，敬请投资者 注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 ...

兰州佛慈制药股份有限公司 2022 年第一季度报告全文 证券代码：002644 证券简称：佛慈制药 公告编号：2022-015 兰州佛慈制药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 236,878,872.61 | 177,434,087.22 | 33.50% | | 归属于上市公司股东的净利润（元） | 21,496,460.61 | 23,105 ...

兰州佛慈制药股份有限公司 2021 年年度报告全文 兰州佛慈制药股份有限公司 2021 年年度报告 2022 年 03 月 1 兰州佛慈制药股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人石爱国、主管会计工作负责人姚毅磊及会计机构负责人(会计主 管人员)王婷声明：保证本年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议。 | | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | --- | | 尚寿鹏 | | 董事 | 身体原因无法现场出席 | 王迎春 | 公司在本报告"第三节 管理层讨论与分析" 中分析了公司未来发展可能面 临的风险因素和应对措施；同时，公司存在财务报告内部控制重大缺陷，具体 内容详见"第四节 公司治理"之"十二、报告期内的内部控制制度建设及实施情 况"。敬请广大投资者予以关 ...

Financial Performance - The company's operating revenue for 2021 was CNY 817,640,826.02, representing a year-on-year increase of 22.39% compared to CNY 668,051,013.92 in 2020[18]. - The net profit attributable to shareholders for 2021 was CNY 93,258,956.07, a decrease of 13.66% from CNY 111,981,040.00 in 2020[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 42,928,548.17, showing a significant increase of 190.68% compared to CNY 18,731,623.70 in 2020[18]. - The net cash flow from operating activities for 2021 was CNY 11,854,642.44, down 81.15% from CNY 62,888,162.80 in 2020[18]. - The total assets at the end of 2021 were CNY 2,352,093,709, reflecting a decrease of 1.47% from CNY 2,387,181,792 at the end of 2020[19]. - The net assets attributable to shareholders at the end of 2021 were CNY 1,614,577,062, an increase of 2.05% from CNY 1,591,159,687 at the end of 2020[19]. - The company reported a total of CNY 50,330,407.90 in non-recurring gains and losses for 2021, compared to CNY 93,249,416.30 in 2020[25]. - In 2021, the company achieved a revenue of CNY 817.64 million, an increase of 22.39% compared to the previous year[41]. - The net profit attributable to shareholders was CNY 93.26 million, a decrease of 13.66% year-on-year[41]. - The pharmaceutical sector contributed CNY 798.52 million, accounting for 97.66% of total revenue, with a year-on-year growth of 20.66%[45]. Dividend and Profit Distribution - The company reported a profit distribution plan based on a total of 510,657,000 shares, proposing a cash dividend of 0.10 RMB per 10 shares (including tax) with no bonus shares issued[5]. - The cash dividend distribution accounted for 100% of the total profit distribution amount[126]. - The company distributed cash dividends of 0.10 yuan per 10 shares, totaling 5,106,570.00 yuan, based on a total share capital of 510,657,000 shares[127]. - The company distributed a total cash dividend of 61.2788 million yuan for the 2020 profit distribution[141]. Internal Control and Governance - The company acknowledged significant internal control deficiencies in financial reporting, which investors should be aware of[5]. - The company has established and revised 209 internal control management systems to enhance operational compliance and risk management[129]. - The company identified one significant defect in financial reporting during the reporting period[135]. - The company reported a total of 1 significant defect and 1 non-financial reporting defect[135]. - The company has implemented measures to correct the identified defects and improve financial reporting accuracy[131]. - The company plans to enhance inter-departmental communication and strengthen investment project tracking management[131]. - The company aims to improve the quality of financial report preparation to ensure accuracy and completeness[131]. - The company will continue to address the identified defects and enhance financial control capabilities[131]. - The company has a comprehensive internal control evaluation report that includes all units with 100% asset and revenue coverage[133]. - The company will disclose the full internal control evaluation report on March 16, 2022[133]. - The company has established standards for identifying defects, categorizing them into significant, important, and general defects[134]. - The company is committed to ensuring that financial reports meet the standards of truthfulness and accuracy[134]. - The company has improved its investor relations management by diversifying communication channels with investors[137]. - The company is committed to improving its governance structure and internal control systems in compliance with relevant laws and regulations[87]. Market and Industry Trends - The pharmaceutical industry in China is experiencing strong growth due to increasing demand driven by economic development and an aging population[28]. - The company is focusing on high-quality development in the traditional Chinese medicine sector, supported by favorable government policies[28]. - In 2021, the Chinese pharmaceutical manufacturing industry achieved a year-on-year value-added growth of 24.8%, with monthly industrial value-added growth exceeding 8% consistently[31]. - The number of new Chinese medicine applications accepted by the CDE reached approximately 1,360, with 60 new drug applications, marking a 114.29% increase from 2020[31]. - The "14th Five-Year" National Medical Security Plan supports the integration of traditional Chinese medicine into the healthcare system, promoting its role in disease prevention and treatment[30]. Research and Development - The company plans to establish a research institute in Shanghai to enhance its R&D capabilities and attract high-quality research talent[33]. - The company has established multiple R&D platforms, including partnerships with several universities to enhance innovation in traditional Chinese medicine[40]. - The company completed the first phase of research on ancient classic prescriptions, aiming to develop new products and enhance its market position[57]. - Research and development expenses increased by 25.84% to ¥19,357,135.92 in 2021, representing 2.37% of operating revenue, compared to 2.30% in 2020[58]. - The number of R&D personnel increased by 7.19% to 164, with the proportion of R&D staff in the total workforce rising to 12.66%[58]. Operational Efficiency and Cost Management - The company achieved a significant increase in manufacturing costs, with total manufacturing expenses rising to ¥140,097,906.30, accounting for 23.57% of operating costs[50]. - The total cost of direct materials was ¥355,702,133.27, accounting for 59.83% of operating costs, an increase from 68.05% in 2020, primarily due to rising raw material prices[50]. - The company plans to enhance its operational efficiency through strategic adjustments and cost management initiatives[160]. - The company has implemented cost control measures that are expected to improve profit margins in the upcoming fiscal year[187]. Social Responsibility and Community Engagement - The company donated over 6 million yuan in pandemic prevention materials during the COVID-19 outbreak[144]. - The company actively engages in social responsibility initiatives, including health lectures and free medical services in rural communities[144]. - The company has employed 100 local farmers through its poverty alleviation initiatives, generating an additional income of CNY 1.8 million for local farmers[146]. - The company conducted technical training for local farmers, benefiting 2,050 impoverished households in mountainous areas[146]. - The company has established a special fund to assist employees in financial difficulties, demonstrating its commitment to employee welfare[142]. Strategic Planning and Future Outlook - The company plans to focus on high-quality development in 2022, emphasizing the integration of its main business sectors and achieving breakthroughs in new product development and market expansion[75]. - The company aims to enhance its marketing management to achieve over 1 billion CNY in market size, single product sales, and customer base[77]. - The company is committed to maintaining a strong financial position while pursuing growth opportunities in emerging markets[188]. - The company has outlined plans for further investment in digital transformation initiatives to enhance customer engagement and operational efficiency[189]. - The company provided optimistic guidance for the next fiscal year, anticipating continued revenue growth[183]. Corporate Governance and Management - The company has a strong emphasis on maintaining a qualified and experienced board of directors and management team to drive strategic decisions[96]. - The management team includes experienced professionals, with the current general manager having served since January 2020[105]. - The board of directors consists of independent directors, ensuring corporate governance and oversight[107]. - The independent directors have extensive backgrounds in finance and law, contributing to strategic decision-making[106]. - The company has a structured remuneration system for directors and senior management based on performance metrics[108]. - The independent directors did not raise any objections regarding company matters during the reporting period[114]. - The board actively monitored the company's operational and financial conditions, ensuring compliance with regulations and internal policies[115]. - The company maintained a focus on risk management and the impact of external factors on its operations[115]. Adjustments and Compliance - The company has made adjustments to its financial statements for previous years due to accounting errors, ensuring compliance with accounting standards[19]. - The company adjusted its financial statements for previous years, impacting the net profit for 2018, 2019, and 2020 by CNY -1,360,373.29, -3,745,541.67, and -3,963,073.09 respectively[155]. - The total assets were adjusted by CNY 2,609,359.03, 85,794,867.83, and 120,049,283.56 for the years 2018, 2019, and 2020 respectively[155]. - The company has implemented new accounting policies in accordance with the revised leasing standards effective from January 1, 2021, with no significant impact on its financial results[153].

兰州佛慈制药股份有限公司 2021 年第三季度报告 兰州佛慈制药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 277,343,937.75 | 59.56% | 664,170,475.25 | 32.22% | | 归属于上市公司股东的 净利润（元） | 22,211,549. ...